These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32160943)

  • 1. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.
    Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
    Semin Arthritis Rheum; 2020 Jun; 50(3):394-400. PubMed ID: 32160943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
    Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
    Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
    Le QA; Hay JW; Becker R; Wang Y
    Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.
    Hiligsmann M; Silverman SS; Singer AJ; Pearman L; Mathew J; Wang Y; Caminis J; Reginster JY
    Pharmacoeconomics; 2023 Jul; 41(7):819-830. PubMed ID: 37086385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.
    Hiligsmann M; Silverman SL; Singer AJ; Pearman L; Wang Y; Caminis J; Reginster JY
    Aging Clin Exp Res; 2024 Jan; 36(1):14. PubMed ID: 38289413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    Bone HG; Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Fitzpatrick LA; Mitlak B; Papapoulos S; Rizzoli R; Dore RK; Bilezikian JP; Saag KG
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2949-2957. PubMed ID: 29800372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.
    Gielen E; Aldvén M; Kanis JA; Borgström F; Senior E; Willems D
    Osteoporos Int; 2024 Jul; 35(7):1173-1183. PubMed ID: 38565690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
    Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
    Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
    Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS
    Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.
    Hiligsmann M; Maggi S; Veronese N; Sartori L; Reginster JY
    Osteoporos Int; 2021 Mar; 32(3):595-606. PubMed ID: 33443610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.
    Mori T; Crandall CJ; Fujii T; Ganz DA
    Arch Osteoporos; 2021 Apr; 16(1):72. PubMed ID: 33866457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
    Reginster JY; Al Daghri N; Kaufman JM; Bruyère O
    Expert Opin Pharmacother; 2018 Feb; 19(2):159-161. PubMed ID: 29251010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
    Leder BZ; Zapalowski C; Hu MY; Hattersley G; Lane NE; Singer AJ; Dore RK
    J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.